MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$39,517K
Proceeds from issuance of
common stock from...
$121K
Proceeds from exercises
of stock options
$33K
Net cash provided by
(used in) financing...
$39,349K
Canceled cashflow
$322K
Net increase
(decrease) in cash and cash...
-$121,869K
Canceled cashflow
$39,349K
Accounts payable
$3,953K
Stock-based compensation
expense
$3,554K
Amortization of debt discount
and costs
$113K
Accrued expenses and
other liabilities
$102K
Loss on foreign
currency exchange
-$86K
Depreciation of property and
equipment
$27K
Income tax and r&d
incentive receivables
-$10K
Payment for debt
issuance costs
$322K
Net cash used in
investing activities
-$149,321K
Net cash used in
operating activities
-$11,897K
Canceled cashflow
$7,845K
Purchases of short-term
investments
$149,321K
Net loss
-$19,014K
Accounts receivable
$524K
Accretion of discounts on
short-term investments
$196K
Prepaid expenses and
other assets
$8K
Back
Back
Cash Flow
source: myfinsight.com
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)